Regional anticoagulation with acid citrate dextrose‐A for extracorporeal photoimmunochemotherapy

Background and Objectives During photopheresis, intravenous heparin is used to prevent clotting in the extracorporeal circuit. Regional citrate anticoagulation could lower the risks associated with heparin treatment.

[1]  Thomas Lang,et al.  Simplified citrate anticoagulation for high-flux hemodialysis. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  R. Apsner,et al.  Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation. , 2001, Blood.

[3]  R. Tigelaar,et al.  Induction of human tumor‐loaded dendritic cells , 2001, International journal of cancer.

[4]  P. Adeleine,et al.  Heparins and blood polymorphonuclear stimulation in haemodialysis: an expansion of the biocompatibility concept. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  T. Price,et al.  Frequency of immediate adverse effects associated with therapeutic apheresis , 1999, Transfusion.

[6]  B. Griffith,et al.  Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. , 1998, The New England journal of medicine.

[7]  H. Hönigsmann,et al.  Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. , 1998, Blood.

[8]  J. van Limbeek,et al.  Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  B. Balda,et al.  Treatment of cutaneous T‐cell lymphoma with extracorporeal photochemotherapy , 1996 .

[10]  W. Hörl,et al.  Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. , 1996, Journal of the American Society of Nephrology : JASN.

[11]  R. Ramakrishna,et al.  Heparin‐induced thrombocytopenia: cross‐reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran) , 1995, British journal of haematology.

[12]  H. Hönigsmann,et al.  Renal allograft rejection controlled by photopheresis , 1995, The Lancet.

[13]  P. Bjerring,et al.  Photopheresis and systemic sclerosis. , 1992, Archives of dermatology.

[14]  J. Hirsh,et al.  Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. , 1992, Chest.

[15]  F. Kerdel,et al.  Pemphigus vulgaris treated with photopheresis. , 1992, Journal of the American Academy of Dermatology.

[16]  F. Trautinger,et al.  Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A pilot study. , 1992, Arthritis and rheumatism.

[17]  K Wolff,et al.  Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. , 1987, The New England journal of medicine.

[18]  M. Flanigan,et al.  Reducing the hemorrhagic complications of hemodialysis: a controlled comparison of low-dose heparin and citrate anticoagulation. , 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  I. Szymanski,et al.  Ionized Calcium During Plateletpheresis , 1978, Transfusion.

[20]  D. S. Hall,et al.  REGIONAL ANTICOAGULATION DURING HEMODIALYSIS USING CITRATE , 1961, The American journal of the medical sciences.

[21]  T. Greenwalt,et al.  American Association of Blood Banks , 1959 .